Abstract
Nine hospitalized schizophrenic patients with tardive dyskinesia were treated with the calcium-channel antagonist verapamil under single-blind conditions. The tardive dyskinesia and activation scores decreased, and the anxiety/depression scores increased. The changes were small but statistically significant.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adult
-
Antipsychotic Agents / adverse effects
-
Anxiety Disorders / psychology
-
Depressive Disorder / psychology
-
Dyskinesia, Drug-Induced / drug therapy*
-
Dyskinesia, Drug-Induced / etiology
-
Dyskinesia, Drug-Induced / psychology
-
Hospitalization
-
Humans
-
Male
-
Middle Aged
-
Psychiatric Status Rating Scales
-
Schizophrenia / drug therapy*
-
Schizophrenic Psychology*
-
Verapamil / therapeutic use*
Substances
-
Antipsychotic Agents
-
Verapamil